400 related articles for article (PubMed ID: 17972172)
21. Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort study.
Saadatmand S; Vos JR; Hooning MJ; Oosterwijk JC; Koppert LB; de Bock GH; Ausems MG; van Asperen CJ; Aalfs CM; Gómez Garcia EB; Meijers-Heijboer H; Hoogerbrugge N; Piek M; Seynaeve C; Verhoef C; Rookus M; Tilanus-Linthorst MM;
Int J Cancer; 2014 Dec; 135(12):2940-9. PubMed ID: 24789418
[TBL] [Abstract][Full Text] [Related]
22. Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers.
Stjepanovic N; Lubinski J; Moller P; Randall Armel S; Foulkes WD; Tung N; Neuhausen SL; Kotsopoulos J; Sun P; Sun S; Eisen A; Narod SA;
Breast Cancer Res Treat; 2021 Jun; 187(2):515-523. PubMed ID: 33423179
[TBL] [Abstract][Full Text] [Related]
23. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Jernström H; Lubinski J; Lynch HT; Ghadirian P; Neuhausen S; Isaacs C; Weber BL; Horsman D; Rosen B; Foulkes WD; Friedman E; Gershoni-Baruch R; Ainsworth P; Daly M; Garber J; Olsson H; Sun P; Narod SA
J Natl Cancer Inst; 2004 Jul; 96(14):1094-8. PubMed ID: 15265971
[TBL] [Abstract][Full Text] [Related]
24. Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.
Wolf I; Laitman Y; Rubinek T; Abramovitz L; Novikov I; Beeri R; Kuro-O M; Koeffler HP; Catane R; Freedman LS; Levy-Lahad E; Karlan BY; Friedman E; Kaufman B
Oncogene; 2010 Jan; 29(1):26-33. PubMed ID: 19802015
[TBL] [Abstract][Full Text] [Related]
25. Clinical and pathological features of BRCA1/2 tumors in a sample of high-risk Moroccan breast cancer patients.
Jouhadi H; Tazzite A; Azeddoug H; Naim A; Nadifi S; Benider A
BMC Res Notes; 2016 Apr; 9():248. PubMed ID: 27129401
[TBL] [Abstract][Full Text] [Related]
26. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
[TBL] [Abstract][Full Text] [Related]
27. Analysis of the pathogenic variants of BRCA1 and BRCA2 using next-generation sequencing in women with familial breast cancer: a case-control study.
Zayas-Villanueva OA; Campos-Acevedo LD; Lugo-Trampe JJ; Hernández-Barajas D; González-Guerrero JF; Noriega-Iriondo MF; Ramírez-Sánchez IA; Martínez-de-Villarreal LE
BMC Cancer; 2019 Jul; 19(1):722. PubMed ID: 31331294
[TBL] [Abstract][Full Text] [Related]
28. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.
Eisen A; Lubinski J; Klijn J; Moller P; Lynch HT; Offit K; Weber B; Rebbeck T; Neuhausen SL; Ghadirian P; Foulkes WD; Gershoni-Baruch R; Friedman E; Rennert G; Wagner T; Isaacs C; Kim-Sing C; Ainsworth P; Sun P; Narod SA
J Clin Oncol; 2005 Oct; 23(30):7491-6. PubMed ID: 16234515
[TBL] [Abstract][Full Text] [Related]
29. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.
Antoniou AC; Beesley J; McGuffog L; Sinilnikova OM; Healey S; Neuhausen SL; Ding YC; Rebbeck TR; Weitzel JN; Lynch HT; Isaacs C; Ganz PA; Tomlinson G; Olopade OI; Couch FJ; Wang X; Lindor NM; Pankratz VS; Radice P; Manoukian S; Peissel B; Zaffaroni D; Barile M; Viel A; Allavena A; Dall'Olio V; Peterlongo P; Szabo CI; Zikan M; Claes K; Poppe B; Foretova L; Mai PL; Greene MH; Rennert G; Lejbkowicz F; Glendon G; Ozcelik H; Andrulis IL; ; Thomassen M; Gerdes AM; Sunde L; Cruger D; Birk Jensen U; Caligo M; Friedman E; Kaufman B; Laitman Y; Milgrom R; Dubrovsky M; Cohen S; Borg A; Jernström H; Lindblom A; Rantala J; Stenmark-Askmalm M; Melin B; ; Nathanson K; Domchek S; Jakubowska A; Lubinski J; Huzarski T; Osorio A; Lasa A; Durán M; Tejada MI; Godino J; Benitez J; Hamann U; Kriege M; Hoogerbrugge N; van der Luijt RB; van Asperen CJ; Devilee P; Meijers-Heijboer EJ; Blok MJ; Aalfs CM; Hogervorst F; Rookus M; ; Cook M; Oliver C; Frost D; Conroy D; Evans DG; Lalloo F; Pichert G; Davidson R; Cole T; Cook J; Paterson J; Hodgson S; Morrison PJ; Porteous ME; Walker L; Kennedy MJ; Dorkins H; Peock S; ; Godwin AK; Stoppa-Lyonnet D; de Pauw A; Mazoyer S; Bonadona V; Lasset C; Dreyfus H; Leroux D; Hardouin A; Berthet P; Faivre L; ; Loustalot C; Noguchi T; Sobol H; Rouleau E; Nogues C; Frénay M; Vénat-Bouvet L; ; Hopper JL; Daly MB; Terry MB; John EM; Buys SS; Yassin Y; Miron A; Goldgar D; ; Singer CF; Dressler AC; Gschwantler-Kaulich D; Pfeiler G; Hansen TV; Jønson L; Agnarsson BA; Kirchhoff T; Offit K; Devlin V; Dutra-Clarke A; Piedmonte M; Rodriguez GC; Wakeley K; Boggess JF; Basil J; Schwartz PE; Blank SV; Toland AE; Montagna M; Casella C; Imyanitov E; Tihomirova L; Blanco I; Lazaro C; Ramus SJ; Sucheston L; Karlan BY; Gross J; Schmutzler R; Wappenschmidt B; Engel C; Meindl A; Lochmann M; Arnold N; Heidemann S; Varon-Mateeva R; Niederacher D; Sutter C; Deissler H; Gadzicki D; Preisler-Adams S; Kast K; Schönbuchner I; Caldes T; de la Hoya M; Aittomäki K; Nevanlinna H; Simard J; Spurdle AB; Holland H; Chen X; ; Platte R; Chenevix-Trench G; Easton DF;
Cancer Res; 2010 Dec; 70(23):9742-54. PubMed ID: 21118973
[TBL] [Abstract][Full Text] [Related]
30. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
31. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
Antoniou A; Pharoah PD; Narod S; Risch HA; Eyfjord JE; Hopper JL; Loman N; Olsson H; Johannsson O; Borg A; Pasini B; Radice P; Manoukian S; Eccles DM; Tang N; Olah E; Anton-Culver H; Warner E; Lubinski J; Gronwald J; Gorski B; Tulinius H; Thorlacius S; Eerola H; Nevanlinna H; Syrjäkoski K; Kallioniemi OP; Thompson D; Evans C; Peto J; Lalloo F; Evans DG; Easton DF
Am J Hum Genet; 2003 May; 72(5):1117-30. PubMed ID: 12677558
[TBL] [Abstract][Full Text] [Related]
32. Young age at first pregnancy does protect against early onset breast cancer in BRCA1 and BRCA2 mutation carriers.
Evans DG; Harkness EF; Howel S; Woodward ER; Howell A; Lalloo F
Breast Cancer Res Treat; 2018 Feb; 167(3):779-785. PubMed ID: 29116468
[TBL] [Abstract][Full Text] [Related]
33. Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Kotsopoulos J; Lubinski J; Salmena L; Lynch HT; Kim-Sing C; Foulkes WD; Ghadirian P; Neuhausen SL; Demsky R; Tung N; Ainsworth P; Senter L; Eisen A; Eng C; Singer C; Ginsburg O; Blum J; Huzarski T; Poll A; Sun P; Narod SA;
Breast Cancer Res; 2012 Mar; 14(2):R42. PubMed ID: 22405187
[TBL] [Abstract][Full Text] [Related]
34. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.
Narod SA; Brunet JS; Ghadirian P; Robson M; Heimdal K; Neuhausen SL; Stoppa-Lyonnet D; Lerman C; Pasini B; de los Rios P; Weber B; Lynch H;
Lancet; 2000 Dec; 356(9245):1876-81. PubMed ID: 11130383
[TBL] [Abstract][Full Text] [Related]
35. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
Kirova YM; Stoppa-Lyonnet D; Savignoni A; Sigal-Zafrani B; Fabre N; Fourquet A;
Eur J Cancer; 2005 Oct; 41(15):2304-11. PubMed ID: 16140006
[TBL] [Abstract][Full Text] [Related]
36. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment.
Robson ME; Chappuis PO; Satagopan J; Wong N; Boyd J; Goffin JR; Hudis C; Roberge D; Norton L; Bégin LR; Offit K; Foulkes WD
Breast Cancer Res; 2004; 6(1):R8-R17. PubMed ID: 14680495
[TBL] [Abstract][Full Text] [Related]
37. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients.
Su L; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Int J Cancer; 2020 Jun; 146(12):3335-3342. PubMed ID: 32037537
[TBL] [Abstract][Full Text] [Related]
38. Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation.
Metcalfe KA; Finch A; Poll A; Horsman D; Kim-Sing C; Scott J; Royer R; Sun P; Narod SA
Br J Cancer; 2009 Jan; 100(2):421-5. PubMed ID: 19088722
[TBL] [Abstract][Full Text] [Related]
39. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers.
Iqbal J; Ragone A; Lubinski J; Lynch HT; Moller P; Ghadirian P; Foulkes WD; Armel S; Eisen A; Neuhausen SL; Senter L; Singer CF; Ainsworth P; Kim-Sing C; Tung N; Friedman E; Llacuachaqui M; Ping S; Narod SA;
Br J Cancer; 2012 Dec; 107(12):2005-9. PubMed ID: 23099806
[TBL] [Abstract][Full Text] [Related]
40. BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma.
Monnerat C; Chompret A; Kannengiesser C; Avril MF; Janin N; Spatz A; Guinebretière JM; Marian C; Barrois M; Boitier F; Lenoir GM; Bressac-de Paillerets B
Fam Cancer; 2007; 6(4):453-61. PubMed ID: 17624602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
